Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006258 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
A Phase 2 study, sponsored by Children's Hospital Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006258: Completed Phase 2 study, sponsored by Children's Hospital Los Angeles.
NCT00006258 is a Phase 2 study that has completed, run by Children's Hospital Los Angeles. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006258, a Phase 2 study, has completed, sponsored by Children's Hospital Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by radiation therapy in treating patients who have surgically resected, newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor, or incompletely resected ependymoma.
Interventions
- DRUG cisplatin
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG methotrexate
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-11 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
What the finished NCT00006258 record still lists
NCT00006258 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00006258 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006258 about?
NCT00006258 is a clinical study titled "Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: ...
What is the current status of trial NCT00006258?
This trial is currently completed. It is a Phase 2 study. The study started on 1997-11. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00006258?
The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), methotrexate (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006258?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia